tradingkey.logo
tradingkey.logo
Search

MoonLake Immunotherapeutics

MLTX
Add to Watchlist
18.440USD
-0.550-2.90%
Close 07-31 16:00ETQuotes delayed by 15 min
1.52BMarket Cap
LossP/E TTM

MLTX Income Statement

You can find the annual or quarterly income statement of MoonLake Immunotherapeutics here for insights into the performance and operational efficiency of MoonLake Immunotherapeutics.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
Operating expenses
47.47%70.02M
31.54%65.22M
65.69%71.43M
98.50%60.70M
139.58%47.48M
229.90%49.58M
232.23%43.11M
131.90%30.58M
53.27%19.82M
-9.99%15.03M
-12.14%12.98M
-25.30%13.19M
-18.89%12.93M
16.94%16.70M
135.68%14.77M
-45.99%17.65M
--15.94M
--14.28M
--6.27M
--32.68M
R&D expenses
49.52%54.52M
38.77%56.01M
69.68%60.63M
110.30%49.76M
180.15%36.46M
398.40%40.36M
371.13%35.74M
171.86%23.66M
75.51%13.01M
-28.77%8.10M
-15.95%7.59M
-23.65%8.70M
-29.08%7.42M
127.72%11.37M
1247.88%9.02M
-61.83%11.40M
--10.45M
--4.99M
--669.53K
--29.87M
Depreciation, depletion, and amortization
123.54%845.00K
-42.29%751.00K
2191.25%745.00K
2539.44%742.00K
1556.95%378.00K
39464.88%1.30M
888.30%32.52K
754.73%28.11K
593.40%22.81K
0.00%3.29K
-0.09%3.29K
0.03%3.29K
32.23%3.29K
32.25%3.29K
45.00%3.29K
--3.29K
--2.49K
--2.49K
--2.27K
----
Other operating expenses
----
----
----
----
----
----
----
----
----
----
----
--0.00
----
----
----
----
----
----
----
----
Operating profit
-47.47%-70.02M
-31.54%-65.22M
-65.69%-71.43M
-98.50%-60.70M
-139.58%-47.48M
-229.90%-49.58M
-232.23%-43.11M
-131.90%-30.58M
-53.27%-19.82M
9.99%-15.03M
12.14%-12.98M
25.30%-13.19M
18.89%-12.93M
-16.94%-16.70M
-135.68%-14.77M
45.99%-17.65M
---15.94M
---14.28M
---6.27M
---32.68M
Net non-operating interest income (expenses)
Non-operating interest expense
12505.56%2.27M
--1.99M
--3.20M
--2.04M
--18.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Other non-operating income (expenses)
-54.80%3.21M
37.70%4.44M
-42.83%4.05M
14.93%6.78M
19.98%7.10M
-55.11%3.23M
411.41%7.09M
599.95%5.90M
717.48%5.92M
2900.28%7.19M
3587.69%1.39M
243.76%842.65K
941.05%723.59K
765.13%239.50K
280.39%37.59K
6584.92%245.13K
--69.51K
---36.01K
---20.84K
---3.78K
Income before tax
-70.98%-69.08M
-35.41%-62.77M
-95.93%-70.58M
-126.73%-55.96M
-190.58%-40.41M
-491.02%-46.35M
-210.79%-36.02M
-99.95%-24.68M
-13.90%-13.91M
52.34%-7.84M
21.33%-11.59M
29.09%-12.34M
23.09%-12.21M
-14.98%-16.46M
-134.30%-14.73M
46.74%-17.41M
---15.87M
---14.31M
---6.29M
---32.69M
Income tax
306.54%622.00K
502.82%248.00K
24.86%115.00K
20.71%95.00K
117.79%153.00K
-7.15%41.14K
218.45%92.11K
675.61%78.70K
538.07%70.25K
302.36%44.31K
230.93%28.92K
9.32%10.15K
50.16%11.01K
131.59%11.01K
--8.74K
--9.28K
--7.33K
--4.75K
--0.00
--0.00
Income after tax
-71.87%-69.71M
-35.83%-63.02M
-95.75%-70.69M
-126.39%-56.05M
-190.21%-40.56M
-488.23%-46.40M
-210.81%-36.11M
-100.42%-24.76M
-14.38%-13.98M
52.10%-7.89M
21.18%-11.62M
29.07%-12.35M
23.05%-12.22M
-15.01%-16.47M
-134.44%-14.74M
46.72%-17.42M
---15.88M
---14.32M
---6.29M
---32.69M
Net income from continuous operations
-71.87%-69.71M
-35.83%-63.02M
-95.75%-70.69M
-126.39%-56.05M
-190.21%-40.56M
-488.23%-46.40M
-210.81%-36.11M
-100.42%-24.76M
-14.38%-13.98M
52.10%-7.89M
21.18%-11.62M
29.07%-12.35M
23.05%-12.22M
-15.01%-16.47M
-134.44%-14.74M
46.72%-17.42M
---15.88M
---14.32M
---6.29M
---32.69M
Other net gains and losses
----
----
----
----
----
----
----
----
----
----
----
---2.00
----
----
----
----
----
----
----
----
Net Income attributable to non-controlling interests
100.00%0.00
25.30%-591.00K
-33.27%-965.00K
-68.99%-831.00K
-103.73%-615.00K
-75.70%-791.19K
66.99%-724.09K
77.79%-491.74K
90.61%-301.87K
96.90%-450.31K
---2.19M
---2.21M
---3.21M
---14.53M
----
----
----
----
----
----
Net income attributable to controlling interests
-74.51%-69.71M
-36.89%-62.43M
-97.03%-69.73M
-127.55%-55.22M
-192.12%-39.94M
-513.20%-45.60M
-275.45%-35.39M
-139.34%-24.27M
-51.85%-13.67M
-284.32%-7.44M
36.06%-9.43M
41.78%-10.14M
43.29%-9.00M
86.48%-1.94M
-134.44%-14.74M
46.72%-17.42M
---15.88M
---14.32M
---6.29M
---32.69M
Net income attributable to common shareholders
-74.51%-69.71M
-36.89%-62.43M
-97.03%-69.73M
-127.55%-55.22M
-192.12%-39.94M
-513.20%-45.60M
-275.45%-35.39M
-139.34%-24.27M
-51.85%-13.67M
-284.32%-7.44M
36.06%-9.43M
41.78%-10.14M
43.29%-9.00M
86.48%-1.94M
-134.44%-14.74M
46.72%-17.42M
---15.88M
---14.32M
---6.29M
---32.69M
Basic earnings per share
-54.83%-0.98
-27.03%-0.92
-95.56%-1.10
-126.08%-0.87
-189.37%-0.63
-483.68%-0.72
-219.46%-0.56
-66.51%-0.39
5.31%-0.22
-155.79%-0.12
55.88%-0.18
53.15%-0.23
46.40%-0.23
87.51%-0.05
-134.44%-0.40
44.11%-0.49
---0.43
---0.39
---0.17
---0.89
Diluted earnings per share
-54.83%-0.98
-27.03%-0.92
-95.56%-1.10
-126.08%-0.87
-189.37%-0.63
-483.68%-0.72
-219.46%-0.56
-66.51%-0.39
5.31%-0.22
-155.79%-0.12
55.88%-0.18
53.15%-0.23
46.40%-0.23
87.51%-0.05
-134.44%-0.40
44.11%-0.49
---0.43
---0.39
---0.17
---0.89
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read MoonLake Immunotherapeutics's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing MLTX stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was MoonLake Immunotherapeutics's net income for the year?

MoonLake Immunotherapeutics posted -227.32M in net income for fiscal year 2025.

How much net income did MoonLake Immunotherapeutics post in the last quarter?

MoonLake Immunotherapeutics reported -69.71M in net income for the latest quarter。

What was MoonLake Immunotherapeutics's annual operating profit?

MoonLake Immunotherapeutics's operating income was -244.83M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.